- With Mayo Clinic nurse educator
Sheryl M. Ness, R.N.
read biographyclose windowBiography of
Sheryl M. Ness, R.N.
Sheryl M. Ness
Sheryl Ness, R.N., O.C.N., is a nurse educator for the Cancer Education Program at Mayo Clinic in Rochester, Minn. She helps inform patients, families and caregivers about services and resources to help them through the cancer journey.
She has a master's degree in nursing from Augsburg College. In addition, she is an assistant professor of oncology at the College of Medicine, Mayo Clinic, and is certified as a specialist in oncology nursing. Sheryl has worked for more than 20 years at Mayo Clinic as an educator. She has a keen interest in the importance of the quality of life and concerns of people living with cancer.
Latest entries
- Genomics study targets women with breast cancer
Oct. 5, 2013
- What's your definition of cancer survivor?
Sept. 28, 2013
- Understanding prostate cancer, one man at a time
Sept. 21, 2013
- What are the ingredients to happiness?
Sept. 14, 2013
- Living with ovarian cancer
Sept. 7, 2013
Free
E-newsletter
Subscribe to Housecall
Our weekly general interest
e-newsletter keeps you up to date
on a wide variety of health topics.
Mayo Clinic Housecall
Stay up to date on the latest health information.
What you get
- Free weekly e-newsletter
- Mayo Clinic expertise
- Recipes, tools and other helpful information
- We do not share your e-mail address
Living with cancer blog
-
Sept. 21, 2013
Understanding prostate cancer, one man at a time
By Sheryl M. Ness, R.N.
Researchers at Mayo Clinic are using genetic sequencing to improve treatments for men with advanced prostate cancer.
Those with advanced prostate cancer can have tumors resistant to standard hormone treatments that lower testosterone. This stage is called castrate-resistant prostate cancer (CRPC) — when hormonal treatments no longer control the cancer.
Using an individualized approach, researchers are attempting to study the genetic changes within the tissue of metastatic prostate cancer tumors to better understand how to treat and gain control of the cancer.
The research is called the Prostate Cancer Medically-Optimized Genome Enhanced Therapy (PROMOTE) study, and is sponsored by the Mayo Clinic Center for Individualized Medicine.
Men with CRPC have many treatment options that can prolong life after hormone therapies stop working. However, there's still no cure for CRPC. Also, there's no way to predict how each patient will respond to each treatment.
The study will attempt to understand how the tumors of those enrolled respond to different treatments, based on the genetic information of their individual tumors.
As part of the research, a biopsy is taken from the one of the sites in the body where the prostate cancer tumors have spread. The tissue is analyzed in the laboratory to study and test which drugs work best against the tumor. Once treatment starts, participants' tumors are closely monitored by medical oncologists with periodic imaging scans to see how the tumors respond to the new treatments.
All men who are diagnosed with castration-resistant prostate cancer are eligible to participate in the study who:
- Have advanced prostate cancer that has stopped responding to hormone treatments.
- Are about to start taking additional medications that target the CYP17 enzyme (abiraterone acetate or Zytiga).
- Agree to undergo two tumor biopsies.
The cost of the drug is covered for the first 12 weeks of the study during which time two tumor biopsies are performed.
PROMOTE aims to help physicians better understand which drugs to prescribe, based on the genetic makeup of each person's individual cancer, and help patients live with a better control of their cancer.
For more information about the PROMOTE study, please call (507) 538-7623 or visit the Center for Individualized Medicine page at Mayo Clinic (http://mayoresearch.mayo.edu/center-for-individualized-medicine/prostate-cancer-study.asp).
Follow me on Twitter at @SherylNess1. Join the discussion at #livingwithcancer.
3 comments posted
Share on:
3 comments posted